Michael Kurin1, Abbinaya Elangovan2, Muhammed Mustafa Alikhan3, Basmah Al Dulaijan3, Eli Silver4, David C Kaelber5, Gregory Cooper6. 1. Division of Gastroenterology and Hepatology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. 2. Internal Medicine-Pediatrics Residency Program, MetroHealth Medical Center, Cleveland, Ohio, USA. 3. Internal Medicine Residency Program, Department of General Internal Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. 4. Division of Pediatric Allergy and Immunology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA. 5. Center for Clinical Informatics Research and Education, The MetroHealth System and Departments of Internal Medicine, Pediatrics and Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA. 6. University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Abstract
BACKGROUND: Mounting evidence supports a mechanistic association between irritable bowel syndrome (IBS) symptoms and mast cell hyperactivity. Yet, association between IBS and mast cell disorders (MCDs) has not been studied. We examined this association using two large databases and verified with manual chart review. METHODS: The IBM Watson Health Explorys database (Somers, NY), an aggregate of electronic health record (EHR) data from over two dozen US healthcare systems, and Epic's SlicerDicer tool, a self-service tool containing de-identified data from the Epic EHR, were used to identify patients with IBS and MCDs. Patients with organic gastrointestinal disease or diseases associated with secondary mast cell hyperproliferation were excluded. Results were verified with manual chart review from two academic centers. KEY RESULTS: Up to 4% of IBS patients had a comorbid MCD. IBS was strongly associated with all MCDs. The strongest association was between IBS and mast cell activation syndrome (OR 16.3; 95% CI 13.1-20.3). Odds ratios for IBS+urticaria, IBS+idiopathic urticaria, IBS+non-malignant mastocytosis, and IBS+mast cell malignancy ranged from 4.5 to 9.9. Patients from each of these overlap cohorts were predominantly female, and the overlap occurred with all IBS subtypes. Thorough endoscopic evaluation and comorbid mood disorders and migraines are more common in the overlap cohorts than in IBS alone. CONCLUSIONS/INFERENCES: In a large US database encompassing >53 million patients over >20 years, patients with IBS are at least 4 times more likely to have a MCD than the general population. Further study of mast cell involvement in the pathogenesis of IBS is warranted.
BACKGROUND: Mounting evidence supports a mechanistic association between irritable bowel syndrome (IBS) symptoms and mast cell hyperactivity. Yet, association between IBS and mast cell disorders (MCDs) has not been studied. We examined this association using two large databases and verified with manual chart review. METHODS: The IBM Watson Health Explorys database (Somers, NY), an aggregate of electronic health record (EHR) data from over two dozen US healthcare systems, and Epic's SlicerDicer tool, a self-service tool containing de-identified data from the Epic EHR, were used to identify patients with IBS and MCDs. Patients with organic gastrointestinal disease or diseases associated with secondary mast cell hyperproliferation were excluded. Results were verified with manual chart review from two academic centers. KEY RESULTS: Up to 4% of IBS patients had a comorbid MCD. IBS was strongly associated with all MCDs. The strongest association was between IBS and mast cell activation syndrome (OR 16.3; 95% CI 13.1-20.3). Odds ratios for IBS+urticaria, IBS+idiopathic urticaria, IBS+non-malignant mastocytosis, and IBS+mast cell malignancy ranged from 4.5 to 9.9. Patients from each of these overlap cohorts were predominantly female, and the overlap occurred with all IBS subtypes. Thorough endoscopic evaluation and comorbid mood disorders and migraines are more common in the overlap cohorts than in IBS alone. CONCLUSIONS/INFERENCES: In a large US database encompassing >53 million patients over >20 years, patients with IBS are at least 4 times more likely to have a MCD than the general population. Further study of mast cell involvement in the pathogenesis of IBS is warranted.
Authors: Peter Valent; Cem Akin; Patrizia Bonadonna; Karin Hartmann; Knut Brockow; Marek Niedoszytko; Boguslaw Nedoszytko; Frank Siebenhaar; Wolfgang R Sperr; Joanna N G Oude Elberink; Joseph H Butterfield; Ivan Alvarez-Twose; Karl Sotlar; Andreas Reiter; Hanneke C Kluin-Nelemans; Olivier Hermine; Jason Gotlib; Sigurd Broesby-Olsen; Alberto Orfao; Hans-Peter Horny; Massimo Triggiani; Michel Arock; Lawrence B Schwartz; Dean D Metcalfe Journal: J Allergy Clin Immunol Pract Date: 2019-02-05
Authors: Ami D Sperber; Shrikant I Bangdiwala; Douglas A Drossman; Uday C Ghoshal; Magnus Simren; Jan Tack; William E Whitehead; Dan L Dumitrascu; Xuicai Fang; Shin Fukudo; John Kellow; Edith Okeke; Eamonn M M Quigley; Max Schmulson; Peter Whorwell; Timothy Archampong; Payman Adibi; Viola Andresen; Marc A Benninga; Bruno Bonaz; Serhat Bor; Luis Bustos Fernandez; Suck Chei Choi; Enrico S Corazziari; Carlos Francisconi; Albis Hani; Leonid Lazebnik; Yeong Yeh Lee; Agata Mulak; M Masudur Rahman; Javier Santos; Mashiko Setshedi; Ari Fahrial Syam; Stephen Vanner; Reuben K Wong; Aurelio Lopez-Colombo; Valeria Costa; Ram Dickman; Motoyori Kanazawa; Ammar Hassanzadeh Keshteli; Rutaba Khatun; Iradj Maleki; Pierre Poitras; Nitesh Pratap; Oksana Stefanyuk; Sandie Thomson; Judith Zeevenhooven; Olafur S Palsson Journal: Gastroenterology Date: 2020-04-12 Impact factor: 22.682
Authors: Annette Fritscher-Ravens; Detlef Schuppan; Mark Ellrichmann; Stefan Schoch; Christoph Röcken; Jochen Brasch; Johannes Bethge; Martina Böttner; Julius Klose; Peter J Milla Journal: Gastroenterology Date: 2014-07-30 Impact factor: 22.682
Authors: G F Stefanini; A Saggioro; V Alvisi; G Angelini; L Capurso; G di Lorenzo; G Dobrilla; M Dodero; M Galimberti; G Gasbarrini Journal: Scand J Gastroenterol Date: 1995-06 Impact factor: 2.423
Authors: M Maurer; M Abuzakouk; F Bérard; W Canonica; H Oude Elberink; A Giménez-Arnau; C Grattan; K Hollis; A Knulst; J-P Lacour; C Lynde; A Marsland; D McBride; A Nakonechna; J Ortiz de Frutos; C Proctor; G Sussman; C Sweeney; H Tian; K Weller; D Wolin; M-M Balp Journal: Allergy Date: 2017-07-10 Impact factor: 13.146